Semin Liver Dis 2014; 34(04): 427-434
DOI: 10.1055/s-0034-1394141
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence

Li-Chun Lu
1   Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2   Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
,
Ann-Lii Cheng
1   Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2   Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
3   Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
,
Ronnie T. P. Poon
4   Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2014 (online)

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. Early-stage HCC can be curatively treated, but the recurrence rate remains high. To date, adjuvant treatments have not proven effective in preventing HCC recurrence after curative treatment. Although early studies explored the potential of vitamin K2, retinoid, chemotherapy, and recently, sorafenib, none of the studies reported successful outcomes. Several new lines of evidence have emerged to support the use of novel antiviral agents for preventing the recurrence of virus-related HCC after curative treatment. In this review, the authors provide a thorough overview of the various adjuvant treatments that have been attempted or are being considered for trial.

 
  • References

  • 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2) 69-90
  • 2 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379 (9822) 1245-1255
  • 3 Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18 (5) 1094-1101
  • 4 Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25 (2) 181-200
  • 5 Kuriyama S, Hitomi M, Yoshiji H , et al. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27 (2) 505-511
  • 6 Ozaki I, Zhang H, Mizuta T , et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res 2007; 13 (7) 2236-2245
  • 7 Mizuta T, Ozaki I, Eguchi Y , et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006; 106 (4) 867-872
  • 8 Hotta N, Ayada M, Sato K , et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54 (79) 2073-2077
  • 9 Kakizaki S, Sohara N, Sato K , et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007; 22 (4) 518-522
  • 10 Yoshiji H, Noguchi R, Toyohara M , et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009; 51 (2) 315-321
  • 11 Ishizuka M, Kubota K, Shimoda M , et al. Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res 2012; 32 (12) 5415-5420
  • 12 Yoshida H, Shiratori Y, Kudo M , et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011; 54 (2) 532-540
  • 13 Zhong JH, Mo XS, Xiang BD , et al. Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS ONE 2013; 8 (3) e58082
  • 14 Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979; 38 (11) 2528-2534
  • 15 Muto Y, Moriwaki H, Ninomiya M , et al; Hepatoma Prevention Study Group. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334 (24) 1561-1567
  • 16 Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340 (13) 1046-1047
  • 17 Takai K, Okuno M, Yasuda I , et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005; 48 (1) 39-45
  • 18 Okita K, Izumi N, Matsui O , et al; Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2014;
  • 19 Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91 (12) 2378-2385
  • 20 Hasegawa K, Takayama T, Ijichi M , et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006; 44 (4) 891-895
  • 21 Xia Y, Qiu Y, Li J , et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 2010; 17 (12) 3137-3144
  • 22 Lau WY, Leung TW, Ho SK , et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353 (9155) 797-801
  • 23 Chung AY, Ooi LL, Machin D , et al. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg 2013; 37 (6) 1356-1361
  • 24 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  • 25 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  • 26 Bruix J, Takayama T, Mazzaferro V , et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32 (5S) 4006
  • 27 Yang Y, Macleod V, Miao HQ , et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 282 (18) 13326-13333
  • 28 Ferro V, Dredge K, Liu L , et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007; 33 (5) 557-568
  • 29 Liu CJ, Lee PH, Lin DY , et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50 (5) 958-968
  • 30 Hsu C, Chen CN, Chen LT , et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65 (3) 242-249
  • 31 Lin AY, Brophy N, Fisher GA , et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103 (1) 119-125
  • 32 Patt YZ, Hassan MM, Lozano RD , et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103 (4) 749-755
  • 33 Ho MC, Hu RH, Ho CM, Chen CN, Chang KJ, Lee PH. A randomized pilot phase II study of thalidomide as adjuvant therapy in patient with high recurrence risk hepatocellular carcinoma. Paper presented at: The International Liver Congress; April 1, 2011; Berlin, Germany
  • 34 Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52 (6) 889-894
  • 35 Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32 (7) 851-858
  • 36 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96 (9) 975-981
  • 37 Sun HC, Tang ZY, Wang L , et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132 (7) 458-465
  • 38 Chen LT, Chen MF, Li LA , et al; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255 (1) 8-17
  • 39 Lo CM, Liu CL, Chan SC , et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245 (6) 831-842
  • 40 Ji J, Shi J, Budhu A , et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361 (15) 1437-1447
  • 41 Hou J, Zhou Y, Zheng Y , et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell 2014; 25 (1) 49-63
  • 42 International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351 (9115) 1535-1539
  • 43 Shiratori Y, Shiina S, Teratani T , et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138 (4) 299-306
  • 44 Mazzaferro V, Romito R, Schiavo M , et al; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (6) 1543-1554
  • 45 Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103 (7) 1663-1673
  • 46 Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg 2010; 14 (7) 1111-1120
  • 47 Sohn W, Paik YH, Kim JM , et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol 2014; 21 (7) 2429-2435
  • 48 Liaw YF, Sung JJ, Chow WC , et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15) 1521-1531
  • 49 Matsumoto A, Tanaka E, Rokuhara A , et al; Inuyama Hepatitis Study Group. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32 (3) 173-184
  • 50 Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53 (1) 118-125
  • 51 Papatheodoridis GV, Dimou E, Dimakopoulos K , et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42 (1) 121-129
  • 52 Chuma M, Hige S, Kamiyama T , et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009; 44 (9) 991-999
  • 53 Chan AC, Chok KS, Yuen WK , et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146 (6) 675-681
  • 54 Wu CY, Chen YJ, Ho HJ , et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308 (18) 1906-1914
  • 55 Wong JS, Wong GL, Tsoi KK , et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33 (10) 1104-1112
  • 56 Yin J, Li N, Han Y , et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013; 31 (29) 3647-3655
  • 57 Hosaka T, Suzuki F, Kobayashi M , et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58 (1) 98-107
  • 58 Huang G, Yang Y, Shen F , et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol 2013; 20 (5) 1482-1490
  • 59 Lee DH, Lee JH, Cho Y , et al. Entecavir treatment significantly reduces the risk of hepatocellular carcinoma recurrence in patients with chronic hepatitis B. Paper presented at: The American Association for the Study of Liver Disease; November 10, 2012 ; Boston, MA
  • 60 Shindoh J, Hasegawa K, Matsuyama Y , et al. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol 2013; 31 (6) 766-773
  • 61 McHutchison JG, Lawitz EJ, Shiffman ML , et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361 (6) 580-593
  • 62 Hadziyannis SJ, Sette Jr H, Morgan TR , et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5) 346-355
  • 63 Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013; 58 (1) 150-157
  • 64 Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368 (20) 1907-1917
  • 65 Sulkowski MS, Gardiner DF, Rodriguez-Torres M , et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370 (3) 211-221
  • 66 Kowdley KV, Gordon SC, Reddy KR , et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370 (20) 1879-1888
  • 67 Poordad F, Hezode C, Trinh R , et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370 (21) 1973-1982
  • 68 Imamura H, Matsuyama Y, Tanaka E , et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38 (2) 200-207
  • 69 Wu JC, Huang YH, Chau GY , et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51 (5) 890-897
  • 70 Hsia CC, Nakashima Y, Tabor E. Deletion mutants of the hepatitis B virus X gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1997; 241 (3) 726-729
  • 71 Huang SF, Chen YT, Lee WC , et al. Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma. PLoS ONE 2014; 9 (2) e89753